Refractory angina – pipeline review, h1 2012


Published on || Refractory Angina – Pipeline Review, H1 2012 || Market Research latest report

Published in: Health & Medicine, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Refractory angina – pipeline review, h1 2012

  1. 1. announces, The Latest market research report is available inits vast collection:Refractory Angina – Pipeline Review, H1 2012You can also request for sample page of above mention reports onsample@aarkstore.comSummaryGlobal Markets Direct’s, Refractory Angina - Pipeline Review, H1 2012, provides anoverview of the Refractory Angina therapeutic pipeline. This report providesinformation on the therapeutic development for Refractory Angina, complete withlatest updates, and special features on late-stage and discontinued projects. It alsoreviews key players involved in the therapeutic development for Refractory Angina.Refractory Angina - Pipeline Review, H1 2012 is built using data and informationsourced from Global Markets Direct’s proprietary databases, Company/Universitywebsites, SEC filings, investor presentations and featured press releases fromcompany/university sites and industry-specific third party sources, put together byGlobal Markets Direct’s team.Note*: Certain sections in the report may be removed or altered based on theavailability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Refractory Angina.- A review of the Refractory Angina products under development by companies anduniversities/research institutes based on information derived from company andindustry-specific sources.- Coverage of products based on various stages of development ranging from
  2. 2. discovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combinedtherapeutics.Table of contents:List of Tables 3List of Figures 3Introduction 4Global Markets Direct Report Coverage 4Refractory Angina Overview 5Therapeutics Development 6An Overview of Pipeline Products for Refractory Angina 6Refractory Angina Therapeutics under Development by Companies 8Mid Clinical Stage Products 9Comparative Analysis 9Refractory Angina Therapeutics – Products under Development by Companies 10Companies Involved in Refractory Angina Therapeutics Development 11Ark Therapeutics Group plc 11Refractory Angina – Therapeutics Assessment 12Assessment by Monotherapy Products 12Assessment by Route of Administration 13Assessment by Molecule Type 15Drug Profiles 17EG011 - Drug Profile 17Product Description 17Mechanism of Action 17R&D Progress 17Refractory Angina Therapeutics - Dormant Products 18Refractory Angina – Product Development Milestones 19Featured News & Press Releases 19Jan 28, 2010: First Refractory Angina Patient Treated With VEGF-D Shortform(EG011) In Phase I/IIa Trial 19Appendix 21Methodology 21Coverage 21
  3. 3. Secondary Research 21Primary Research 21Expert Panel Validation 21Contact Us 22Disclaimer 22List of FiguresList of Tables are also include.For more related Reports Plz follow The link:Pipeline Review, H1 2012 Review, H12012&PubId=&pagenum=1Refractory Angina – Pipeline Review, H1 2012Post-Myocardial Infarction – Pipeline Review, H1 2012Proteinuria – Pipeline Review, H1 2012Ocular Pain – Pipeline Review, H1 2012Pediculosis (Head Lice Infestation) – Pipeline Review, H1 2012Allergic Rhino-Conjunctivitis – Pipeline Review, H1 2012Acquired (Autoimmune) Hemolytic Anemia – Pipeline Review, H1 2012
  4. 4. Thyroid Gland Disorders – Pipeline Review, H1 2012Tinea Corporis – Pipeline Review, H1 2012Pulmonary Fibrosis – Pipeline Review, H1 2012Search More Reports Related to This Category :Pharmaceuticals and Healthcare andHealthcare&PubId=&pagenum=1For More details Plz do contact :Aarkstore EnterpriseLavanyaPhone:08149852585Email: